Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic endothelial progenitor cells
- Development stage
- Unknown
- Lead developer
- Chengnuo Regenerative Medicine Technology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intra-arterial, Intralesional
01
Overview
Allogeneic endothelial progenitor cells (EPCs) are a cell therapy product consisting of precursor cells that differentiate into mature endothelial cells to facilitate vascular repair and neovascularization. The specific candidate developed by Chengnuo Regenerative Medicine is derived from human induced pluripotent stem cells (iPSCs), providing a scalable and standardized source of cells. These EPCs are designed to treat ischemic conditions by integrating into damaged blood vessels and secreting pro-angiogenic factors that stimulate the growth of new vasculature. The therapy is currently being evaluated in clinical trials for acute ischemic stroke, critical limb ischemia (CLI), and erectile dysfunction.
- Other names
- allogeneic endothelial progenitor cells injectionallogeneic EPCsiPSC-derived allogeneic endothelial progenitor cells
Beyond the preview
Go deeper on allogeneic endothelial progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic endothelial progenitor cells.